Business Context and Reporting Period
Company: MedaSorb Technologies Corporation (operating as Cytosorbents Corp in metadata, though filing lists MedaSorb Technologies Corporation).
Reporting Period: Quarterly period ended June 30, 2008 (Form 10-Q).
Status: Development stage company with no commercial revenue to date. The company is focused on the research, development, and commercialization of blood purification technology, specifically the CytoSorb device for treating sepsis and other acute conditions. Operations are conducted through a wholly-owned subsidiary.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 | Balance Sheet (June 30, 2008) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(1,501,727) | $(2,162,583) | N/A |
| Net Loss Available to Common Shareholders | $(2,082,868) | $(2,536,081) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $3,593,748 |
| Total Assets | N/A | N/A | $4,145,389 |
| Total Liabilities | N/A | N/A | $1,226,768 |
| Accumulated Deficit | N/A | N/A | $(73,621,077) |
| Operating Cash Flow | $(887,570) | $(1,373,533) | N/A |
| Financing Cash Flow | $4,279,603 | $0 | N/A |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $211,613 at December 31, 2007, to $3,593,748 at June 30, 2008. This was driven by a $4.45 million private placement of Series B Preferred Stock completed in June 2008.
- Equity Position: Stockholders' equity turned from a deficit of $(104,296) at year-end 2007 to a positive balance of $2,918,621, primarily due to the capital raise and issuance of preferred stock.
- Expense Reduction: Net loss for the six months ended June 30, 2008, decreased to $(1.50 million) compared to $(2.16 million) in the same period in 2007. Total expenses were $1.78 million in 2008 versus $2.16 million in 2007.
- Debt Conversion: Promissory notes totaling $175,000 plus accrued interest were converted into Series B Preferred Stock during the period.
Outlook, Risks, and Management Commentary
- Going Concern: The company has a history of negative cash flows and an accumulated deficit of over $73 million. While the recent financing improved liquidity, management states there can be no assurance that additional capital will be available on favorable terms or at all to fund future operations.
- Regulatory Strategy: The company is prioritizing regulatory approval in Europe (CE Mark) over the U.S. (FDA) for its CytoSorb device, believing the European pathway is faster. A clinical study in Germany involving up to 80 patients was approved, with six patients enrolled as of the filing date.
- Legal Proceedings: A trademark infringement lawsuit filed by Alkermes, Inc. regarding the name "MedaSorb" was settled in June 2008. The parent company retains the name, but the operating subsidiary has ceased using "MedaSorb" to avoid confusion.
- Preferred Stock Terms: The Series B Preferred Stock carries a 10% dividend (increasing to 20% upon default), payable in additional shares. It includes liquidation preferences, voting rights on an as-converted basis, and redemption rights after five years.
Investor Verification Checklist
- Capital Runway: Verify if the $3.6 million cash balance is sufficient to fund the European clinical trials and operations until the next anticipated financing round.
- Dilution Risk: Assess the impact of the 10% cumulative dividends on Series B Preferred Stock (paid in shares) and the conversion of $4.45 million of preferred stock into common stock at $0.035 per share.
- Regulatory Milestones: Monitor the progress of the German clinical trial and the timeline for obtaining the CE Mark, as commercialization is entirely dependent on this approval.
- Trademark Settlement: Confirm the long-term implications of the name change for the operating subsidiary on brand recognition and marketing.
- Warrant Overhang: Review the significant number of outstanding warrants (approx. 26 million common shares and additional preferred warrants) and their potential dilutive effect upon exercise.